

EISAI TO ESTABLISH NEW PARENTERAL FACILITY IN CHINA

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that it has decided to establish a new parenteral facility (below, “New Plant”) on a lot retained by Eisai’s Chinese subsidiary, Eisai China Inc., at the Suzhou Industrial Park in Suzhou, Jiangsu, China.

Eisai currently retains a production facility (below, “Suzhou Plant”) nearby the site scheduled for construction of the New Plant; the Suzhou Plant operates as a solid preparation production and packaging base that supplies domestic demand in China. Eisai’s decision to establish the New Plant is aimed at constructing a stable supply chain for injection products in China in expectation of future sustained growth in the Chinese pharmaceutical market, particularly a forecasted increase in demand for Methycobal[®] injection, one of Eisai’s major products in China, as a drug for peripheral neuropathies. The move is also expected to achieve cost reduction at the New Plant through improving production efficiency in the mid-term. Injection products produced at the New Plant going forward will also be considered for supply to emerging countries, including in Asia and Central and South America, with the goal of having the New Plant function as a global supply base.

The New Plant will be built on an approximately 132,000 m² lot purchased by Eisai in 2010. The facility will stand two floors aboveground, contain a building area of approximately 2,500 m², and initially operate as a

[Notes to editors]

1. Outline of Suzhou Plant

- 1) Location: 32 Baiyu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China
- 2) Construction completed: June 1998 / Launch of operations: May 1999
- 3) Main products:
 - Solid preparations for Chinese market: Methycobal[®], Aricept[®], Pariet[®]
 - Packaging for Chinese market: Methycobal[®] injection, Stronger Neo-Minophagen[®] C, Glycyron[®]
- 4) Site area: Approximately 25,000 m²

2. Outline of New Plant

- 1) Location: 168 Xingpu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China
- 2) Construction to begin: 3Q FY2013 (planned) / Construction to be completed: 1st half of FY2014 (planned)
- 3) Main products:
 - Injection product for Chinese market: Methycobal[®] injection
- 4) Site area: Approximately 132,000 m² / Building area: Approximately 2,500 m²